Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The biotech industry has been a robust roller-coaster ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

The Invesco Pharmaceuticals ETF (NYSEMKT:PJP) offers concentrated exposure to established, profitable drugmakers with lower volatility, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) ...

The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...

The iShares Biotechnology ETF offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller innovators. IBB is cap-weighted and top-heavy, ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...